
BEIJING, May 17 (Xinhua) -- Three COVID-19 vaccines have entered phase II clinical trials in Beijing, said a municipal health official on Sunday.
Xu Qiang, head of the Beijing Municipal Science and Technology Commission, said that Beijing has arranged 21 science and technology projects in response to the novel coronavirus epidemic.
Five innovative drugs have been approved for clinical trials, and all of them have entered phase II clinical studies, he said at a routine press conference on COVID-19 prevention and control.
According to a three-year action plan on strengthening the emergency management system for public health security in the capital (2020-2022), Xu said Beijing will establish a linkage mechanism for prevention, clinical practice, scientific research, treatment and project emergency approval.
Beijing will accelerate the research and development of diagnostic reagents, drugs, vaccines and medical equipment, and support pharmaceutical and vaccine manufacturers in expanding their capacity to meet demands.
Beijing will improve the layout of biosafety level-3 (BSL-3) labs.
Xu said that Beijing will strengthen the supportive role of new technologies such as big data, artificial intelligence, 5G and the Internet of Things in epidemic monitoring and analysis, virus tracing, prevention, control and treatment.
Fire brigade in Shanghai holds group wedding
Tourists enjoy ice sculptures in Datan Town, north China
Sunset scenery of Dayan Pagoda in Xi'an
Tourists have fun at scenic spot in Nanlong Town, NW China
Harbin attracts tourists by making best use of ice in winter
In pics: FIS Alpine Ski Women's World Cup Slalom
Black-necked cranes rest at reservoir in Lhunzhub County, Lhasa
China's FAST telescope will be available to foreign scientists in April
"She power" plays indispensable role in poverty alleviation
Top 10 world news events of People's Daily in 2020
Top 10 China news events of People's Daily in 2020
Top 10 media buzzwords of 2020
Year-ender:10 major tourism stories of 2020
No interference in Venezuelan issues
Biz prepares for trade spat
Broadcasting Continent
Australia wins Chinese CEOs as US loses